Literature DB >> 25452512

What's new in multiple sclerosis?

Lilia G Dimitrov1, Benjamin Turner2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25452512      PMCID: PMC4240117          DOI: 10.3399/bjgp14X682609

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  11 in total

Review 1.  The changing demographic pattern of multiple sclerosis epidemiology.

Authors:  Nils Koch-Henriksen; Per Soelberg Sørensen
Journal:  Lancet Neurol       Date:  2010-05       Impact factor: 44.182

2.  Urinary tract infection in multiple sclerosis: a practical algorithm for a common problem.

Authors:  A-H Maghzi; A Minagar
Journal:  Eur J Neurol       Date:  2012-08-20       Impact factor: 6.089

3.  A primary care-based needs assessment of people with multiple sclerosis.

Authors:  K MacLurg; P Reilly; S Hawkins; O Gray; E Evason; D Whittington
Journal:  Br J Gen Pract       Date:  2005-05       Impact factor: 5.386

4.  Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Authors:  Feng Pan; Jo Wern Goh; Gary Cutter; Wayne Su; Dirk Pleimes; Cheng Wang
Journal:  Clin Ther       Date:  2012-08-18       Impact factor: 3.393

5.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

Authors:  L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

6.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

7.  Better MS services.

Authors:  Jennifer Trueland
Journal:  Nurs Stand       Date:  2014 Mar 5-11

8.  Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.

Authors:  Orla Tuohy; Lisa Costelloe; Grant Hill-Cawthorne; Ingunn Bjornson; Katharine Harding; Neil Robertson; Karen May; Tom Button; Laura Azzopardi; Onajite Kousin-Ezewu; Michael T Fahey; Joanne Jones; D Alastair S Compston; Alasdair Coles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-21       Impact factor: 10.154

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

View more
  3 in total

1.  A Bio-Psycho-Social Co-created Intervention for Young Adults With Multiple Sclerosis (ESPRIMO): Rationale and Study Protocol for a Feasibility Study.

Authors:  Valeria Donisi; Alberto Gajofatto; Maria Angela Mazzi; Francesca Gobbin; Isolde Martina Busch; Annamaria Ghellere; Alina Klonova; Doriana Rudi; Francesca Vitali; Federico Schena; Lidia Del Piccolo; Michela Rimondini
Journal:  Front Psychol       Date:  2021-02-23

2.  Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.

Authors:  Aya A Elkhodiry; Hend M El Tayebi
Journal:  Noncoding RNA Res       Date:  2021-12-07

3.  Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies.

Authors:  Jiwon Oh; Sandra Vukusic; Klaus Tiel-Wilck; Jihad Said Inshasi; David Rog; Darren P Baker; Yelena Pyatkevich; Elizabeth M Poole; Patrick Vermersch
Journal:  J Cent Nerv Syst Dis       Date:  2021-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.